H. Hansen

发表

H. Hansen, M. Ro̸rth, 1990, Cancer chemotherapy and biological response modifiers.

Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease.

I. Strøyer, H. Hansen, N. Nissen, 1975, Cancer chemotherapy reports.

Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients.

N. Brünner, H. Hansen, H. Pappot, 1997, European journal of cancer.

Chemotherapy in adenocarcinoma of the lung.

H. Hansen, J. Sørensen, 1989, Cancer Surveys.

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.

H. Hansen, N. Thatcher, H. Anderson, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The 2nd workshop on small cell carcinoma of the lung gleneagles, Scotland, September 1984

H. Hansen, J. Smyth, 1985 .

Phase I clinical trial of a single-dose and two weekly schedules of ICRF-159 (NSC-129943).

H. Hansen, S. Taylor, O. Selawry, 1974, Cancer chemotherapy reports.

Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression

F. Hirsch, H. Hansen, P. Dombernowsky, 1999, British Journal of Cancer.

Intratumoral pharmacokinetic analysis by 19F-magnetic resonance spectroscopy and cytostatic in vivo activity of gemcitabine (dFdC) in two small cell lung cancer xenografts.

H. Hansen, P. Kristjansen, B. Quistorff, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.

H. Hansen, F. Muggia, O. Selawry, 1972, Cancer chemotherapy reports.

Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.

N. Brünner, H. Hansen, K. Danø, 1994, Cancer research.

Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.

N. Brünner, H. Hansen, K. Danø, 1994, Cancer research.

CONCENTRATION OF LITHIUM, SODIUM AND POTASSIUM IN EPITHELIAL CELLS OF THE ISOLATED FROG SKIN DURING ACTIVE TRANSPORT OF LITHIUM.

H. Hansen, K. Zerahn, 1964, Acta physiologica Scandinavica.

Cell kinetic studies in patients with small cell carcinoma of the lung

H. Hansen, F. Muggia, S. Krezoski, 1974, Cancer.

Non-small-cell lung cancer--stalemate or progress?

H. Hansen, D. Carney, 2000, The New England journal of medicine.

Commentary: current status of chemotherapy for non-small cell lung cancer.

H. Hansen, J. Aisner, 1981, Cancer treatment reports.

Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients.

H. Hansen, M. Hansen, P. Dombernowsky, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study.

H. Hansen, M. Hansen, P. Dombernowsky, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of advanced non-small cell lung cancer

H. Hansen, 2002, BMJ : British Medical Journal.

Epidemiology and Aetiology

H. Hansen, 1990 .

Frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma

H. Hansen, S. Newman, 1974 .

Metastatic patterns in small-cell lung cancer: correlation of autopsy findings with clinical parameters in 537 patients.

F. Hirsch, H. Hansen, J. Elliott, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone‐marrow examination in the staging of small‐cell anaplastic carcinoma of the lung with special reference to subtyping: An evaluation of 203 consecutive patients

F. Hirsch, H. Hansen, P. Dombernowsky, 1977, Cancer.

Clinical studies with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037).

H. Hansen, F. Muggia, O. Selawry, 1971, Cancer research.

Is there a role for chemotherapy of non-small cell lung cancer?

H. Hansen, 1995, Annals of Oncology.

L-asparaginase toxicity.

H. Hansen, P. Carbone, C. Haskell, 1969, Cancer research.

Clinical study with bleomycin: Tolerance to twice weekly dosage

V. Devita, H. Hansen, F. Muggia, 1972, Cancer.

The incidence of osseous involvement in lung cancer, with special reference to the development of osteoblastic changes.

H. Hansen, H. Twigg, L. Napoli, 1973, Radiology.

Prevention, early detection and screening

P. Bunn, H. Hansen, 2005 .

Lung Cancer

H. Hansen, M. Ro̸rth, 1990, European Commission Series for General Practitioners.

Early Detection: Screening

H. Hansen, S. Spiro, 1988 .

Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants.

P. Andersen, H. Hansen, P. Dombernowsky, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients.

H. Hansen, P. Dombernowsky, B. Bergman, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of low‐dose topotecan in second‐line treatment for patients with epithelial ovarian carcinoma

H. Hansen, C. Høgdall, S. Engelholm, 2002, Cancer.

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor.

H. Hansen, J. Verweij, H. Rosing, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment policy of surgery in small cell carcinoma of the lung: retrospective analysis of a series of 874 consecutive patients.

H. Hansen, M. Ro̸rth, P. Dombernowsky, 1985, Thorax.

Proceedings: Frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma.

H. Hansen, S. Newman, 1974, Cancer.

PET/CT imaging in response evaluation of patients with small cell lung cancer.

H. Hansen, J. Mortensen, A. Loft, 2006, Lung cancer.

Prophylactic irradiation in bronchogenic small cell anaplastic carcinoma. A comparative trial of localized versus extensive radiotherapy including prophylactic brain irradiation in patients receiving combination chemotherapy

F. Hirsch, H. Hansen, P. Dombernowsky, 1980, Cancer.

A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis.

H. Hansen, J. Mortensen, B. Fischer, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Single-agent chemotherapy for advanced adenocarcinoma of the lung

H. Hansen, M. Clerici, J. Sørensen, 1988, Cancer Chemotherapy and Pharmacology.

Phase-I study of α-1,3,5-Triglycidyl-s-triazinetrione (NSC 296934)

H. Hansen, P. Dombernowsky, B. Lund, 2004, Cancer Chemotherapy and Pharmacology.

Combination chemotherapy for advanced adenocarcinoma of the lung

H. Hansen, J. Sørensen, 1988, Cancer Chemotherapy and Pharmacology.

Epirubicin in colorectal cancer

F. Cavalli, H. Hansen, H. Pinedo, 2004, Investigational New Drugs.

Phase II study of teniposide in adenocarcinoma of the lung

H. Hansen, P. Dombernowsky, J. Sørensen, 2004, Cancer Chemotherapy and Pharmacology.

Tallysomycin S10b — a phase I trial

H. Hansen, H. Pedersen, P. Sørensen, 2004, Cancer Chemotherapy and Pharmacology.

Phase II trial of high-dose cisplatin plus ifosfamide as first-line followed by carboplatin as second-line treatment in epithelial ovarian carcinoma.

H. Hansen, G. Strauss, B. Lund, 1997, Gynecologic Oncology.

Evaluation of the optimal duration of chemotherapy in phase II trials for inoperable non-small-cell lung cancer (NSCLC).

H. Hansen, P. Dombernowsky, J. Sørensen, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Prospective evaluation of the effect on initial brain metastases from small cell lung cancer of platinum-etoposide based induction chemotherapy followed by an alternating multidrug regimen.

H. Hansen, P. Kristjansen, P. Soelberg Sørensen, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Ceftriaxone versus latamoxef in febrile neutropenic patients: empirical monotherapy in patients with solid tumours.

H. Hansen, P. Dombernowsky, P. Oturai, 1993, European journal of cancer.

A phase I clinical and pharmacokinetic study of Brequinar sodium, DUP 785 (NSC 368390), using a weekly and a biweekly schedule.

H. Hansen, E. Bork, S. Vest, 1989, European journal of cancer & clinical oncology.

Etoposide (VP-16) in the treatment of lung cancer.

H. Hansen, A. Pedersen, 1983, Cancer treatment reviews.

Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments.

H. Hansen, M. Sehested, P. B. Jensen, 1994, Cancer research.

Development of Brain Metastases in Small-Cell Anaplastic Carcinoma of the Lung

O. Paulson, F. Hirsch, H. Hansen, 1979 .

Detection of liver metastases in small-cell lung cancer: a comparison of peritoneoscopy with liver biopsy and ultrasonography with fine-needle aspiration.

H. Hansen, S. W. Hansen, N. T. Pedersen, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of peplomycin in squamous cell carcinoma of the lung.

H. Hansen, M. Ro̸rth, P. Dombernowsky, 1983, European journal of cancer & clinical oncology.

Phase I evaluation of peplomycin with special reference to pulmonary toxicity.

H. Hansen, M. Ro̸rth, P. Sørensen, 1983, European journal of cancer & clinical oncology.

New cytostatic drugs in ovarian cancer.

M. Piccart, E. Eisenhauer, J. Neijt, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer workshop.

H. Hansen, J. Smyth, J. Aisner, 1983, Cancer treatment reports.

Bone-marrow examination in 100 consecutive patients with bronchogenic carcinoma.

H. Hansen, F. Muggia, O. Selawry, 1971, Lancet.

Metastatic spinal cord compression secondary to lung cancer.

P. Sørensen, H. Hansen, P. Dombernowsky, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

E-38. Historical milestones in small cell lung cancer

H. Hansen, 2003 .

The clinical relevance of recent developments in pathology and biology of small cell lung cancer.

F. Hirsch, H. Hansen, F. Hirsch, 1989, Chest.

Brain metastases from small cell lung cancer treated with combination chemotherapy.

H. Hansen, P. Kristjansen, 1988, European journal of cancer & clinical oncology.

Clinical study of vincristine in adenocarcinoma of the lung. A study of the Early-Clinical-Trial Group of the E.O.R.T.C.

H. Hansen, A. Brugarolas, P. Siegenthalen, 1980, European journal of cancer.

Peritoneoscopy in the staging of 190 patients with small‐cell anaplastic carcinoma of the lung with special reference to subtyping

F. Hirsch, H. Hansen, P. Dombernowsky, 1978, Cancer.

Vinca alkaloids in the treatment of non-small cell lung cancer.

H. Hansen, J. Sørensen, K. Osterlind, 1987, Cancer treatment reviews.

Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer.

H. Hansen, C. Høgdall, S. Engelholm, 2001, Gynecologic oncology.

Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer

M. Highley, F. Hirsch, J. Carmichael, 2001, Anti-cancer drugs.

Surgery in limited stage small cell lung cancer.

H. Hansen, U. Lassen, 1999, Cancer treatment reviews.

Second IASLC Workshop on combined Radiotherapy and Chemotherapy Modalities in Lung Cancer. Treatment evaluation.

M. Parmar, R. Arriagada, J. Pignon, 1994, Lung Cancer.

Lung Cancer: Basic and Clinical Aspects

H. Hansen, Heine Høi Hansen, 1986, Cancer Treatment and Research.

Phase II study of vindesine, cisplatin, and hexamethylmelamine (VCH) in small cell carcinoma of the lung.

H. Hansen, M. Ro̸rth, G. Daugaard, 1984, Cancer treatment reports.

Cyclic alternating 'non-cross resistant' chemotherapy in the management of small cell anaplastic carcinoma of the lung.

H. Hansen, K. Osterlind, J. Elliott, 1984, Cancer Treatment Reviews.

Vindesine in the treatment of small cell anaplastic bronchogenic carcinoma.

H. Hansen, P. Dombernowsky, K. Osterlind, 1981, Cancer treatment reports.

Misonidazole combined with radiotherapy in the treatment of inoperable squamous cell carcinoma of the lung a double‐blind randomized trial

H. Hansen, J. Panduro, M. Kjaer, 2006, Cancer.

Chemotherapy of advanced small-cell anaplastic carcinoma. Superiority of a four-drug combination to a three-drug combination.

F. Hirsch, H. Hansen, P. Dombernowsky, 1978, Annals of internal medicine.

Bone marrow involvement in small cell anaplastic carcinoma of the lung. Prognostic and therapeutic aspects

F. Hirsch, H. Hansen, 1980, Cancer.

A clinical model for quality of life assessment in cancer patients receiving chemotherapy.

D. Machin, M. King, H. Hansen, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Patterns of failure in small cell lung cancer: implications for therapy.

H. Hansen, J. Elliott, 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Brain metastases in small-cell lung cancer.

H. Hansen, P. Kristjansen, U. Lassen, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Diagnosis of liver metastases in bronchogenic carcinoma: A comparative study of liver scans, function tests, and peritoneoscopy with liver biopsy in 111 patients

H. Hansen, F. Muggia, S. Kanhouwa, 1974, Cancer.

Management of lung cancer.

H. Hansen, 1977, The Medical clinics of North America.

Is there a role for vindesine in the treatment of non-small cell lung cancer?

H. Hansen, J. Sørensen, 1993, Investigational New Drugs.

Randomized, double-blind comparison of granisetron versus granisetron plus prednisolone as antiemetic prophylaxis during multiple-day cisplatin-based chemotherapy

H. Hansen, J. Herrstedt, J. Handberg, 1997, Supportive Care in Cancer.

Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma.

H. Hansen, F. Bach, E. Bork, 1985, Cancer treatment reports.

Phase II study of amsacrine in solid tumors: a report of the EORTC Early Clinical Trial-Group.

F. Cavalli, M. van Glabbeke, H. Hansen, 1983, European journal of cancer & clinical oncology.

Reduced variation in the clonogenic assay obtained by standardization of the cell culture conditions prior to drug testing on human small cell lung cancer cell lines

H. Hansen, I. Christensen, P. B. Jensen, 1989, Investigational New Drugs.

Doxorubicin sensitivity pattern in a panel of small-cell lung-cancer cell lines: correlation to etoposide and vincristine sensitivity and inverse correlation to carmustine sensitivity

H. Hansen, I. Christensen, M. Sehested, 2004, Cancer Chemotherapy and Pharmacology.

Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.

H. Hansen, I. Christensen, M. Sehested, 1993, British Journal of Cancer.

In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL).

H. Hansen, M. Sehested, P. B. Jensen, 1989, British Journal of Cancer.

Recurrent epithelial ovarian cancer: validation and improvement of an established prognostic index.

H. Hansen, I. Christensen, C. Høgdall, 2005, European journal of obstetrics, gynecology, and reproductive biology.

The superiority of CCNU in the treatment of advanced hodgkin's disease: Cancer and leukemia group b study

T. Pajak, H. Hansen, C. Spurr, 1981, Cancer.

Psycho-Oncology and Communication

J. Armitage, F. Cavalli, H. Hansen, 2009 .

Tumour markers in the clinical management of patients with small cell lung cancer.

H. Hansen, M. Hansen, 1989, The European respiratory journal.

An international survey on attitudes in the control of lung cancer a collaborative study between WHO and I.A.S.L.C.

H. Hansen, K. Stanley, 1985 .

Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up.

F. Hirsch, H. Hansen, P. Kristjansen, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Update in Chemotherapy

H. Hansen, 1986 .

What are the Results

H. Hansen, 1990 .

Should maintenance chemotherapy be used to treat small cell lung cancer?

F. Hirsch, H. Hansen, J. Sculier, 1998, European journal of cancer.

Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?

J. Hilden, H. Hansen, E. Høgdall, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intensive combined chemotherapy and radiotherapy in patients with nonresectable bronchogenic carcinoma

H. Hansen, F. Muggia, O. Selawry, 1972, Cancer.

Comparison of clinical neurological function and CT response during chemotherapy for initial brain metastases from small cell lung cancer

H. Hansen, P. Kristjansen, P. S. Sørensen, 1994, Acta neurologica Scandinavica.

Chemotherapy of small cell lung cancer.

H. Hansen, P. Kristjansen, 1991, European journal of cancer.

Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer.

H. Hansen, P. Dombernowsky, J. Sørensen, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer

H. Hansen, P. Dombernowsky, J. Sørensen, 1999 .

Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer

H. Hansen, P. Dombernowsky, B. Bergman, 1999, British Journal of Cancer.

Staging procedures and prognostic features in small cell anaplastic bronchogenic carcinoma.

F. Hirsch, H. Hansen, P. Dombernowsky, 1978, Seminars in oncology.

Staging of inoperable patients with bronchogenic carcinoma with special reference to bone marrow examination and peritoneoscopy

H. Hansen, F. Muggia, 1972, Cancer.

Management of Relapsed Small-Cell Lung Cancer

H. Hansen, M. Sorensen, 2006 .

5-FU in the treatment of small cell anaplastic carcinoma of the lung: a phase II trial.

H. Hansen, M. Ro̸rth, P. Dombernowsky, 1981, Cancer treatment reports.

Severe intracellular magnesium and potassium depletion in patients after treatment with cisplatin

N. Secher, H. Hansen, H. Bundgaard, 2003, British Journal of Cancer.

Treatment of malignant germ cell tumors.

H. Hansen, M. Ro̸rth, G. Daugaard, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation

H. Hansen, M. Spang‐Thomsen, P. B. Jensen, 2004, Cancer Chemotherapy and Pharmacology.

The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung

H. Hansen, I. Christensen, M. Spang‐Thomsen, 2004, Cancer Chemotherapy and Pharmacology.

Chemotherapy in small cell lung cancer: a consensus report

M. Fukuoka, P. Bunn, H. Hansen, 1989 .

Changing concepts in the management of patients with lung cancer

H. Hansen, P. Kristjansen, 1988, The Medical journal of Australia.

Phase II study of teniposide in small cell carcinoma of the lung.

H. Hansen, P. Dombernowsky, K. Osterlind, 1984, Cancer treatment reports.

Phase II clinical trial of VP-16-213 in ovarian cancer.

H. Hansen, J. Armand, A. Lacave, 1981, Cancer treatment reports.

Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.

H. Hansen, B. Lund, O. P. Hansen, 1992, Seminars in oncology.

High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease.

H. Hansen, B. Lund, O. P. Hansen, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of the cisplatin analogue 1,1-diamminomethylcyclohexane sulfatoplatinum (TNO-6) (NSC 311056)

H. Hansen, M. Ro̸rth, J. Sørensen, 2004, Cancer Chemotherapy and Pharmacology.

The cytotoxic activity of cisplatin, carboplatin and teniposide alone and combined determined on four human small cell lung cancer cell lines by the clonogenic assay.

H. Hansen, I. Christensen, M. Spang‐Thomsen, 1988, European journal of cancer & clinical oncology.

A phase II study of ifosfamide, carboplatin and cisplatin in advanced and recurrent squamous cell carcinoma of the uterine cervix.

H. Hansen, M. Ro̸rth, S. Aage Engelholm, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of 9-hydroxy-2N-methylellipticinium acetate.

F. Cavalli, H. Hansen, A. Brugarolas, 1984, European Journal of Cancer and Clinical Oncology.

Cell proliferation and histologic classification of bronchogenic carcinoma.

H. Hansen, P. Dombernowsky, B. Hainau, 1977, Journal of the National Cancer Institute.

cis-Dichlorodiammineplatinum (II) and hexamethylmelamine in advanced ovarian carcinoma: a phase II study.

H. Hansen, M. Ro̸rth, B. Lund, 1982, European journal of cancer & clinical oncology.

Combination chemotherapy in the management of superior vena caval obstruction in small-cell anaplastic carcinoma of the lung.

H. Hansen, P. Dombernowsky, 2009, Acta medica Scandinavica.

Prophylactic cranial irradiation and small cell lung cancer.

H. Hansen, P. Kristjansen, A. Pedersen, 1988, Cancer treatment reviews.

Therapy of Lung Cancer-Any progress? An Overview of the Last Decade

H. Hansen, M. Ro̸rth, 1986 .

Management of small-cell cancer of the lung

H. Hansen, 1992, The Lancet.

Combination chemotherapy of advanced lung cancer. A randomized trial

H. Hansen, R. Simon, D. Carr, 1976, Cancer.

Central Nervous System Metastases in Small Cell Carcinoma of the Lung — A Review

O. Paulson, F. Hirsch, H. Hansen, 1980 .

Management of small cell lung cancer : Third IASLC Workshop on Small Cell Lung Cancer, Elsinore, Denmark, 18-22 June, 1989

H. Hansen, P. Kristjansen, 1989 .

cis-Dichlorodiammineplatinum (II) in small cell anaplastic bronchogenic carcinoma: a phase II study.

H. Hansen, P. Dombernowsky, J. Aisner, 1979, Cancer treatment reports.

Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP‐16‐213 (NSC 141540, 4′‐demethylepipodophyllotoxin 9‐(4,6‐0‐ethylidene‐β‐D‐glucopyranoside)

F. Hirsch, H. Hansen, P. Dombernowsky, 1977, Cancer.

Small cell carcinoma of the lung: serum calcitonin and serum histaminase (diamine oxidase) at basal levels and stimulated by pentagastrin.

H. Hansen, N. Tryding, M. Hansen, 2009, Acta medica Scandinavica.

More power to trials for non-small-cell lung cancer.

H. Hansen, J. Sørensen, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Lung Cancer Therapy Annual 2000

H. Hansen, 2000 .

Phase II trial of epirubicin in advanced squamous, adeno- and large cell carcinoma of the lung.

H. Hansen, M. Rozencweig, R. Joss, 1984, European journal of cancer & clinical oncology.

Small Cell Anaplastic Carcinoma of the Lung: Staging

H. Hansen, P. Dombernowsky, 1981 .

Phase I clinical trial of isophosphamide (NSC-109724).

H. Hansen, F. Muggia, A. Mittelman, 1975, Cancer chemotherapy reports.

Combined high-dose carboplatin and cisplatin, and ifosfamide in previously untreated ovarian cancer patients with residual disease.

H. Hansen, B. Lund, O. P. Hansen, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Magnesium and potassium homeostasis during cisplatin treatment

H. Hansen, M. Kristensen, G. Daugaard, 2005, Cancer Chemotherapy and Pharmacology.

Phase II study of oral VP-16-213 in hepatocellular carcinoma.

F. Cavalli, H. Hansen, A. Goldhirsch, 1981, European journal of cancer & clinical oncology.

Treatment at the Finsen Institute

F. Hirsch, H. Hansen, M. Ro̸rth, 1988 .

Inter-experiment variation and dependence on culture conditions in assaying the chemosensitivity of human small cell lung cancer cell lines.

H. Hansen, M. Spang‐Thomsen, H. Roed, 1987, European journal of cancer & clinical oncology.

The Variability of Individual Tolerance to Methotrexate in Cancer Patients

H. Hansen, J. Holland, O. Selawry, 1971, British Journal of Cancer.

In vitro evaluation of a new nitrosourea, TCNU, against human small cell lung cancer cell lines

H. Hansen, I. Christensen, M. Spang‐Thomsen, 2004, Cancer Chemotherapy and Pharmacology.

A phase I clinical evaluation of 1-(2-chloroethyl)-3-[2-(dimethylaminosulphonyl)ethyl]-1-nitrosou rea (TCNU).

H. Hansen, J. Vibe-Petersen, E. Bork, 1987, European journal of cancer & clinical oncology.

Mepacrine hydrochloride in the treatment of malignant pleural effusion. A controlled randomized trial.

H. Hansen, J. Mejer, K. Mortensen, 1977, Scandinavian journal of respiratory diseases.

Commentary (Hansen)—Limited Small-Cell Lung Cancer: A Potentially Curable Disease

Frcp, H. Hansen, 2000 .

Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.

H. Hansen, M. Sehested, P. B. Jensen, 1990, Cancer research.

Letter: Ectopic production of calcitonin.

H. Hansen, F. Muggia, 1973, Lancet.

Current status of research into small cell carcinoma of the lung: summary of the Second Workshop of the International Association for the Study of Lung Cancer (IASLC).

H. Hansen, J. Smyth, 1985, European journal of cancer & clinical oncology.

Endometrial Cancer

H. Hansen, H. Suit, Maryanne Bombaugh, 1989, Cancer Treatment and Reasearch.

Advanced non-small-cell lung cancer: to treat or not to treat?

H. Hansen, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II.

H. Hansen, M. Sehested, K. Wassermann, 1991, Cancer research.

1-2(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, NSC-79037): a comparison of drug administration at four-week and six-week intervals.

H. Hansen, L. Broder, 1973, European journal of cancer.

RISK OF THERAPY-RELATED LEUKAEMIA AND PRELEUKAEMIA AFTER HODGKIN'S DISEASE Relation to Age, Cumulative Dose of Alkylating Agents, and Time from Chemotherapy

H. Hansen, L. Specht, S. Larsen, 1987, The Lancet.

Second-line chemotherapy in small cell lung cancer.

H. Hansen, P. Kristjansen, M. Andersen, 1990, Cancer treatment reviews.

A phase I evaluation of N10-propargyl-5,8-dideazafolic acid.

H. Hansen, S. Vest, E. Bork, 1988, European journal of cancer & clinical oncology.

Hormonal polypeptides and amine metabolites in small cell carcinoma of the lung, with special reference to stage and subtypes

J. M. Christensen, F. Hirsch, H. Hansen, 1980, Cancer.

Treatment of malignant brain tumors with nitrosoureas.

H. Hansen, F. Muggia, 1971, Cancer chemotherapy reports.

Ectopic placental proteins in nontrophoblastic tumors. Serial measurements following chemotherapy

B. Weintraub, H. Hansen, F. Muggia, 1975, Cancer.

Phase I study of single, escalating doses of a superantigen-antibody fusion protein (PNU-214565) in patients with advanced colorectal or pancreatic carcinoma.

H. Hansen, J. Zeuthen, S. E. Nielsen, 2000, Journal of immunotherapy.

Testicular carcinoma in Denmark 1976-1980. Stage and selected clinical parameters at presentation.

H. Hansen, H. Schultz, H. Barlebo, 1984, Acta radiologica. Oncology.

Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis.

H. Hansen, P. Dombernowsky, J. Sørensen, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic instability of cell lines derived from a single human small cell carcinoma of the lung.

N. Brünner, N. Tommerup, H. Hansen, 1985, European journal of cancer & clinical oncology.

Therapy of extragonadal germ-cell tumors.

H. Hansen, M. Ro̸rth, G. Daugaard, 1983, European journal of cancer & clinical oncology.

IV international conference on prevention and early detection of lung cancer, Reykjavik, Iceland, August 9-12, 2001.

E. Dmitrovsky, C. Henschke, F. Hirsch, 2002, Lung cancer.

Clonal heterogeneity of small-cell anaplastic carcinoma of the lung demonstrated by flow-cytometric DNA analysis.

F. Hirsch, H. Hansen, I. Christensen, 1980, Cancer research.

Neuron specific enolase, carcinoembryonic antigen and lactate dehydrogenase as indicators of disease activity in small cell lung cancer.

H. Hansen, E. Cooper, L. G. Jørgensen, 1989, European journal of cancer & clinical oncology.

Dianhydrogalactitol (NSC-132313): phase II study in solid tumors.

F. Cavalli, H. Hansen, A. Brugarolas, 1979, European Journal of Cancer.

Phase II study of anhydro-ara-5-fluorocytidine in adenocarcinoma of gastrointestinal tract, epidermoid carcinoma of lung, head and neck, breast carcinoma and small cell anaplastic carcinoma of lung. A study report of the E.O.R.T.C. early clinical trial cooperative group.

F. Cavalli, H. Hansen, R. Sylvester, 1978, European journal of cancer.

Systemic chemotherapy of brain metastases from small-cell lung cancer: a review.

H. Hansen, P. Kristjansen, C. Kristensen, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Small cell lung cancer: biological and therapeutic aspects.

H. Hansen, H. Poulsen, C. Kristensen, 1996, Critical reviews in oncology/hematology.

Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial.

P. Sørensen, H. Hansen, H. Mouridsen, 1994, European journal of cancer.

Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark.

J. Olsen, F. Hirsch, H. Hansen, 2002, Lung cancer.

A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer.

H. Hansen, N. Thatcher, H. Anderson, 1996, British Journal of Cancer.

Prognostic impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma.

F. Hirsch, B. Skov, H. Hansen, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Prophylactic cranial irradiation in small cell lung cancer--an update.

H. Hansen, P. Kristjansen, Heine H. Hansen, 1995, Lung cancer.

Performance status rather than age is the key prognostic factor in second‐line treatment of elderly patients with epithelial ovarian carcinoma

H. Hansen, C. Høgdall, S. Engelholm, 2002, Cancer.

Phase II study of 1,2,4-triglycidylurazol (TGU) in previously untreated and treated patients with small cell lung cancer.

H. Hansen, F. Hansen, B. Lund, 1987, European journal of cancer & clinical oncology.

Primary resistance of renal adenocarcinoma to 1,2,4-triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent--a phase II study of the EORTC early clinical trials group.

M. van Glabbeke, H. Hansen, H. Pinedo, 1986, European journal of cancer & clinical oncology.

Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease

H. Hansen, M. Andersen, J. Sørensen, 1995, Journal of internal medicine.

Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?

H. Hansen, E. Høgdall, C. Høgdall, 2004, British Journal of Cancer.

Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine).

H. Hansen, P. Kristjansen, B. Lund, 1993, Cancer treatment reviews.

Biocmical and pharmacologic effects of L-asparaginase in man.

H. Hansen, C. Haskell, G. Canellos, 1970, The Journal of laboratory and clinical medicine.

Twenty-five years of chemotherapy in small cell lung cancer sends us back to the laboratory.

H. Hansen, M. Sehested, P. B. Jensen, 1999, Cancer treatment reviews.

TREATMENT OF SMALL-CELL CARCINOMA OF BRONCHUS

H. Hansen, P. Dombernowsky, F. Muggia, 1975, The Lancet.

Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung.

F. Hirsch, H. Hansen, M. Ro̸rth, 1983, Cancer research.

Long-term survival in small cell carcinoma of the lung.

H. Hansen, P. Dombernowsky, M. Hansen, 1980, JAMA.

Response to cytostatic treatment in inoperable adenocarcinoma of the lung: critical implications.

H. Hansen, J. Badsberg, J. B. SÃ¸rensen, 1989, British Journal of Cancer.

Chemotherapy for adenocarcinoma of the lung (WHO III): A randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs.

H. Hansen, P. Dombernowsky, J. Sørensen, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?

H. Hansen, I. Christensen, C. Høgdall, 2004, Gynecologic oncology.

Performance status assessment in cancer patients. An inter-observer variability study.

H. Hansen, T. Palshof, J. Sørensen, 1993, British Journal of Cancer.

Superiority of high-dose platinum (cisplatin and carboplatin) compared to carboplatin alone in combination chemotherapy for small-cell lung carcinoma: a prospective randomised trial of 280 consecutive patients.

F. Hirsch, H. Hansen, P. Dombernowsky, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Multiple endocrine adenomatosis of mixed type.

H. Hansen, O. P. Hansen, B. Rose, 2009, Acta medica Scandinavica.

The prognostic significance of histopathologic subtyping of small cell carcinoma of the lung according to the classification of the world health organization. A study of 375 consecutive patients

F. Hirsch, H. Hansen, K. Østerlind, 1983, Cancer.

Keynote address on chemotherapy for lung cancer.

H. Hansen, 1973, Cancer chemotherapy reports. Part 3.

Mortality and morbidity in long-term surviving patients treated with chemotherapy with or without irradiation for small-cell lung cancer.

H. Hansen, P. Dombernowsky, K. Osterlind, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of surgical resection prior to chemotherapy on the long-term results in small cell lung cancer. A study of 150 operable patients.

H. Hansen, P. Dombernowsky, K. Osterlind, 1986, European journal of cancer & clinical oncology.

Hypercalcemia in epidermoid tumors of the head and neck and esophagus

H. Hansen, F. Muggia, R. Stephens, 1973, Cancer.

Determinants of complete remission induction and maintenance in chemotherapy with or without irradiation of small cell lung cancer.

P. Andersen, H. Hansen, P. Dombernowsky, 1987, Cancer research.

The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: a randomized trial of 288 consecutive patients.

F. Hirsch, H. Hansen, P. Dombernowsky, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SMALL-CELL CARCINOMA OF THE BRONCHUS

H. Hansen, M. Ro̸rth, P. Dombernowsky, 1980, The Lancet.

Vincristine (NSC-67574) in the treatment of small-cell anaplastic carcinoma of the lung.

H. Hansen, P. Dombernowsky, B. Hainau, 1976, Cancer treatment reports.

Treatment of small-cell carcinoma of the lung monitored by sequential flow cytometric DNA analysis.

F. Hirsch, H. Hansen, N. Nissen, 1982, Cancer research.

Intracranial metastases in small cell carcinoma of the lung. Correlation of clinical and autopsy findings

H. Hansen, O. Paulson, J. Vraa-Jensen, 1982, Cancer.

Staging and Prognosis

F. Hirsch, H. Hansen, M. Ro̸rth, 1988 .

Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer. Results of a controlled trial with 5 years follow-up.

H. Hansen, M. Ro̸rth, P. Dombernowsky, 1986, British Journal of Cancer.

Combination chemotherapy for malignant thymoma.

H. Hansen, M. Ro̸rth, G. Daugaard, 1983, Annals of internal medicine.

Chemotherapy in malignant mesothelioma: a review

H. Hansen, A. Krarup-Hansen, 2004, Cancer Chemotherapy and Pharmacology.

A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer.

F. Hirsch, H. Hansen, P. B. Jensen, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Epirubicin in colorectal cancer. A phase II study of the early clinical trials group (EORTC).

F. Cavalli, H. Hansen, H. Høst, 1985, Investigational new drugs.

Phase II study of 4′-iodo-4′-deoxydoxorubicin in non-resectable non-small-cell lung cancer

H. Hansen, P. Dombernowsky, J. Sørensen, 2004, Cancer Chemotherapy and Pharmacology.

In vivo inhibition of etoposide-mediated apoptosis, toxicity, and antitumor effect by the topoisomerase II-uncoupling anthracycline aclarubicin

H. Hansen, M. Sehested, P. B. Jensen, 2004, Cancer Chemotherapy and Pharmacology.

Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance.

H. Hansen, M. Sehested, E. Kjeldsen, 1993, Biochemical pharmacology.

16 Randomized trial in small cell lung cancer comparing the combination of cisplatin and carboplatin with carboplatin alone in combination chemotherapy

F. Hirsch, H. Hansen, P. Dombernowsky, 1997 .

The epipodophyllotoxin derivatives VM26 and VP16: Experimental and clinical aspects

H. Hansen, P. Dombernowsky, 1989, European journal of haematology. Supplementum.

Osteoblastic metastases in small‐cell (OAT‐cell) carcinoma of the lung

H. Hansen, Franco M. Muggia, 1972, Cancer.

Chromosome Aberrations and pharmacokinetics in patients receiving tauromustine as either a single or a repeated dose

H. Hansen, K. Hansson, P. Gunnarsson, 1996, Cancer Chemotherapy and Pharmacology.

Serum neuron-specific enolase (S-NSE) in progressive small-cell lung cancer (SCLC).

H. Hansen, E. Cooper, K. Osterlind, 1994, British Journal of Cancer.

Letter: Treatment of small-cell carcinoma of bronchus.

H. Hansen, P. Dombernowsky, F. Muggia, 1975, Lancet.

Vindesine in the treatment of squamous cell carcinoma, adenocarcinoma, and large cell carcinoma of the lung.

H. Hansen, M. Ro̸rth, P. Dombernowsky, 1982, Cancer treatment reports.

The prognostic influence of serum neuron specific enolase in small cell lung cancer.

H. Hansen, E. Cooper, K. Osterlind, 1988, British Journal of Cancer.

The impact of abdominal computerized tomography on the pretreatment staging and prognosis of small cell lung cancer.

F. Hirsch, H. Hansen, C. Thomsen, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

84 Phase II study of topotecan in refractory and sensitive small cell lung cancer (SCLC)

P. Postmus, H. Hansen, J. Wanders, 1995 .

Management of small cell lung cancer: a summary of the Third International Association for the Study of Lung Cancer Workshop on Small Cell Lung Cancer.

H. Hansen, P. Kristjansen, 1990, Journal of the National Cancer Institute.

Serum neuron specific enolase (NSE) is a determinant of response duration in small cell lung cancer (SCLC).

H. Hansen, E. Cooper, K. Osterlind, 1992, British Journal of Cancer.

An Update on Management of Lung Cancer

H. Hansen, 2002 .

Radical radiotherapy and chemotherapy in localized inoperable non-small-cell lung cancer: a randomized trial.

A. Gregor, H. Hansen, F. Macbeth, 1993, Journal of the National Cancer Institute.

Should initial treatment of small cell carcinoma include systemic chemotherapy and brain irradiation?

H. Hansen, 1973, Cancer chemotherapy reports. Part 3.

Original article: Combination chemotheraphy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens

F. Hirsch, H. Hansen, P. Dombernowsky, 1991 .

Consensus report on combined radiotherapy and chemotherapy modalities in lung cancer.

J. Goldie, R. Souhami, R. Arriagada, 1988, Antibiotics and chemotherapy.

The effect of gemcitabine in non-small cell lung cancer

H. Hansen, 1997 .

Magnesium depletion enhances cisplatin-induced nephrotoxicity.

H. Hansen, S. Nielsen, M. Kristensen, 2005, Cancer Chemotherapy and Pharmacology.

What are the Symptoms

H. Hansen, Heine H. Hansen, 1990 .

In vitro and in vivo evaluation of the indoloquinone EO-9 (NSC 382 459) against human small cell carcinoma of the lung.

H. Hansen, M. Spang‐Thomsen, H. Roed, 1989, European journal of cancer & clinical oncology.

Management of Small Cell Lung Cancer

H. Hansen, 1990 .

Treatment of small cell carcinoma of the lung.

H. Hansen, 1984, Gan to kagaku ryoho. Cancer & chemotherapy.

Phase II trial of prednimustine (NSC-134087) in the treatment of small-cell anaplastic carcinoma of the lung

H. Hansen, P. Dombernowsky, H. Jensen, 2004, Cancer Chemotherapy and Pharmacology.

Chemotherapy for symptom control in advanced NSCLC

M. Ranson, H. Hansen, N. Thatcher, 1997 .

Phase II trial of amsacrine (m-AMSA) in advanced ovarian carcinoma.

H. Hansen, P. Dombernowsky, R. Somers, 1982, European journal of cancer & clinical oncology.

Phase II study of diamino-dichlorophenyl-methylpyrimidine (DDMP) with folinic acid (CF) protection and rescue.

F. Cavalli, H. Hansen, A. Brugarolas, 1980, European journal of cancer.

Unpredictable hematologic toxicity of weekly ddmp.

H. Hansen, M. E. Lau, M. Hansen, 1978, Cancer treatment reports.

Cyclophosphamide and the urinary bladder.

H. Hansen, F. Muggia, N. Saini, 1971, The New England journal of medicine.

Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidine- -D-glucopyranoside) (NSC-122819).

H. Hansen, F. Muggia, O. Selawry, 1971, Cancer chemotherapy reports.

Intracranial metastases in small cell carcinoma of the lung prognostic aspects

F. Hirsch, H. Hansen, O. Paulson, 1983, Cancer.

BILATERAL BONE‐MARROW EXAMINATIONS IN SMALL‐CELL ANAPLASTIC CARCINOMA OF THE LUNG

F. Hirsch, H. Hansen, B. Hainau, 1979, Acta pathologica et microbiologica Scandinavica. Section A, Pathology.

The Radner needle a bone-marrow biopsy device.

H. Hansen, N. Nissen, P. Dombernowsky, 2009, Scandinavian journal of haematology.

Early detection of bone-marrow invasion in oat-cell carcinoma of the lung.

H. Hansen, F. Muggia, 1971, The New England journal of medicine.

Hydronephrosis in advanced ovarian carcinoma.

H. Hansen, B. Lund, 1989, Gynecologic oncology.

L-asparaginase treatment of acute myeloblastic leukemia.

H. Hansen, G. Canellos, 1970, Oncology.

Textbook of Lung Cancer

H. Hansen, Heine H. Hansen, 1999 .

Phase II study of procarbazine in small cell carcinoma of the lung.

H. Hansen, P. Dombernowsky, K. Aabo, 1982, Cancer treatment reports.

Textbook of medical oncology

H. Hansen, S. Kaye, F. Cavalli, 2009 .

Acute nonlymphocytic leukemia, preleukemia, and solid tumors following intensive chemotherapy of small cell carcinoma of the lung.

H. Hansen, J. Pedersen‐Bjergaard, P. Philip, 1985, Blood.

Treatment dilemmas in "non-small cell" lung cancer.

H. Hansen, J. Sørensen, 1990, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Cerebrospinal fluid bombesin and calcitonin in patients with central nervous system metastases from small-cell lung cancer.

A. Gazdar, A. Gazdar, P. Sørensen, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of characteristics of human small cell carcinoma of the lung in patients, in vitro and transplanted into nude mice.

N. Brünner, F. Hirsch, H. Hansen, 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section A, Pathology.

The epipodophyllotoxin derivatives VM-26 and VP-16-213, 1976-1979, a review.

H. Hansen, N. Nissen, P. Dombernowsky, 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Quality of life and supportive care

H. Hansen, M. Paesmans, T. Berghmans, 2008 .

A randomized study of single agent vs combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma.

N. Nielsen, H. Hansen, P. Dombernowsky, 1985, European Journal of Cancer and Clinical Oncology.

Current therapy of small cell lung cancer.

H. Hansen, U. Lassen, M. Sorensen, 1998, Current Opinion in Oncology.

Screening and early detection

P. Bunn, H. Hansen, 2000 .

[Percutaneous transluminal coronary angioplasty in acute myocardial infarction. A prospective controlled study].

H. Hansen, K. Rasmussen, L. Thuesen, 1998, Ugeskrift for laeger.

Intestinal obstruction in patients with advanced carcinoma of the ovaries treated with combination chemotherapy.

N. Nielsen, H. Hansen, F. Lundvall, 1989, Surgery, gynecology & obstetrics.

BONE-MARROW DEPRESSION BY LONG-ACTING DIAMINOPYRIMIDINES

H. Hansen, M. Hansen, 1977, The Lancet.

Cerebrospinal fluid ACTH and calcitonin in patients with CNS metastases from small cell bronchogenic carcinoma.

H. Hansen, L. Hummer, M. Hansen, 1980, European journal of cancer.

A randomized study of sequential versus alternating combination chemotherapy in advanced ovarian carcinoma.

N. Nielsen, H. Hansen, H. Thomsen, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Re-induction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer (EOC)

H. Hansen, C. Høgdall, S. Engelholm, 2001 .

Initial clinical trial of dibromodulcitol (NSC-104800) in patients with advanced cancer.

H. Hansen, O. Selawry, J. Keyes, 1971, Cancer chemotherapy reports.

Combined high-dose platinum and etoposide in previously untreated ovarian cancer patients with residual disease

H. Hansen, G. Strauss, B. Lund, 1996, International Journal of Gynecologic Cancer.

Who is at High Risk

H. Hansen, 1990 .

Recombinant interferon A (IFL-rA) therapy of small cell and squamous cell carcinoma of the lung. A phase II study.

H. Hansen, M. Nissen, P. Ernst, 1987, European journal of cancer & clinical oncology.

Prophylactic lrradia tion in Bronc hogenic Small Cell Anaplastic Carcinoma

F. Hirsch, H. Hansen, P. Dombernowsky, 2006 .

Growth characteristics and heterogeneity of small cell carcinoma of the lung.

H. Hansen, M. Spang‐Thomsen, L. Vindeløv, 1985, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Chemotherapy of small cell carcinoma: a review.

H. Hansen, 1987, The Quarterly journal of medicine.

Histopathologic Typing of Lung Cancer

H. Hansen, 1986 .

Histopathologic typing of lung cancer. Etiologic and epidemiologic features

H. Hansen, 1986 .

Bone marrow examination in small cell lung cancer.

F. Hirsch, H. Hansen, P. Kristjansen, 1987, Annals of Internal Medicine.

Management of advanced metastatic germ cell tumours.

H. Hansen, M. Ro̸rth, G. Daugaard, 1987, International journal of andrology.

Phase I trial of a new form of an oral administration of VP-16-213.

H. Hansen, N. Nissen, H. Pedersen, 1979, Cancer treatment reports.